Jose A Villadangos

List of Publications by Year in Descending Order

146 papers	12,231 citations	56 h-index	109 g-index
169 ext. papers	13,536 ext. citations	11.3 avg, IF	6.14 L-index

#	Paper	IF	Citations
146	Spatiotemporal Adaptations of Macrophage and Dendritic Cell Development and Function.. *Annual Review of Immunology*, **2022**,	34.7	5
145	Marginal zone B cells acquire dendritic cell functions by trogocytosis.. *Science*, **2022**, 375, eabf7470	33.3	8
144	Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86.. *Nature Communications*, **2022**, 13, 1934	17.4	1
143	Varicella zoster virus impairs expression of the non-classical major histocompatibility complex class I-related gene protein (MR1). *Journal of Infectious Diseases*, **2021**,	7	1
142	Physiological substrates and ontogeny-specific expression of the ubiquitin ligases MARCH1 and MARCH8.. *Current Research in Immunology*, **2021**, 2, 218-228	1	3
141	Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT. *Science Immunology*, **2021**, 6,	28	3
140	CD36 family members are TCR-independent ligands for CD1 antigen-presenting molecules. *Science Immunology*, **2021**, 6,	28	3
139	Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. *Immunology and Cell Biology*, **2021**, 99, 962-971	5	5
138	MHC Class II Ubiquitination Regulates Dendritic Cell Function and Immunity. *Journal of Immunology*, **2021**, 207, 2255-2264	5.3	2
137	Regulation of dendritic cell function by Fc-□receptors and the neonatal Fc receptor. *Molecular Immunology*, **2021**, 139, 193-201	4.3	1
136	MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	1
135	Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. *Nature Immunology*, **2020**, 21, 636-648	19.1	56
134	A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver T Cell-Mediated Immunity against Malaria in Mice. *Cell Host and Microbe*, **2020**, 27, 950-962.e7	23.4	21
133	Organ-specific isoform selection of fatty acid-binding proteins in tissue-resident lymphocytes. *Science Immunology*, **2020**, 5,	28	42
132	MR1: a multi-faceted metabolite sensor for T cell activation. *Current Opinion in Immunology*, **2020**, 64, 124-129	7.8	8
131	Virus-Mediated Suppression of the Antigen Presentation Molecule MR1. *Cell Reports*, **2020**, 30, 2948-2962.e4	8.64	15
130	RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells. *ELife*, **2020**, 9,	8.9	3

129	Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. *Science*, **2020**, 367,	33.3	129
128	Absence of mucosal-associated invariant T cells in a person with a homozygous point mutation in. *Science Immunology*, **2020**, 5,	28	19
127	Endoplasmic reticulum chaperones stabilize ligand-receptive MR1 molecules for efficient presentation of metabolite antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 24974-24985	11.5	13
126	Ubiquitination of MHC Class II Is Required for Development of Regulatory but Not Conventional CD4 T Cells. *Journal of Immunology*, **2020**, 205, 1207-1216	5.3	4
125	Downregulation of MHC Class I Expression by Influenza A and B Viruses. *Frontiers in Immunology*, **2019**, 10, 1158	8.4	28
124	Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. *Lancet Respiratory Medicine,the*, **2019**, 7, 710-720	35.1	34
123	MARCH ligases in immunity. *Current Opinion in Immunology*, **2019**, 58, 38-43	7.8	19
122	Membrane-associated RING-CH (MARCH) proteins down-regulate cell surface expression of the interleukin-6 receptor alpha chain (IL6R). *Biochemical Journal*, **2019**, 476, 2869-2882	3.8	6
121	MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. *PLoS ONE*, **2018**, 13, e0200540	3.7	19
120	Ubiquitin Ligase MARCH8 attenuates Graft versus Host Disease via Regulation of Gut Epithelial Cell Surface MHC II Expression.. *Transplantation*, **2018**, 102, S300	1.8	1
119	MR1 antigen presentation to MAIT cells: new ligands, diverse pathways?. *Current Opinion in Immunology*, **2018**, 52, 108-113	7.8	16
118	Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes. *Molecular Immunology*, **2017**, 81, 143-150	4.3	11
117	Reply to: "Differential expression of serpins may selectively license distinct granzyme B functions including antigen cross-presentation". *Molecular Immunology*, **2017**, 87, 327-328	4.3	
116	Serpinb9 is a marker of antigen cross-presenting dendritic cells. *Molecular Immunology*, **2017**, 82, 50-56	4.3	11
115	DNA-based probes for flow cytometry analysis of endocytosis and recycling. *Traffic*, **2017**, 18, 242-249	5.7	8
114	Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections. *Immunity*, **2017**, 47, 135-147.e5	32.3	83
113	How MR1 Presents a Pathogen Metabolic Signature to Mucosal-Associated Invariant T (MAIT) Cells. *Trends in Immunology*, **2017**, 38, 679-689	14.4	17
112	The MARCH family joins the antigen cross-presentation party. *Immunology and Cell Biology*, **2017**, 95, 737-738	5	

111	Dendritic Cell Migration and Antigen Presentation Are Coordinated by the Opposing Functions of the Tetraspanins CD82 and CD37. *Journal of Immunology*, **2016**, 196, 978-87	5.3	28
110	Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis. *Immunological Reviews*, **2016**, 272, 169-82	11.3	9
109	The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. *Nature Immunology*, **2016**, 17, 531-7	19.1	92
108	Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model. *Journal of Immunology*, **2016**, 196, 3935-42	5.3	8
107	Understanding host-pathogen interaction. *Intensive Care Medicine*, **2016**, 42, 2084-2086	14.5	6
106	Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. *Journal of Experimental Medicine*, **2016**, 213, 1695-703	16.6	42
105	MR1 presentation of vitamin B-based metabolite ligands. *Current Opinion in Immunology*, **2015**, 34, 28-34	7.8	36
104	Modulation of antigen presentation by intracellular trafficking. *Current Opinion in Immunology*, **2015**, 34, 16-21	7.8	27
103	Differential use of autophagy by primary dendritic cells specialized in cross-presentation. *Autophagy*, **2015**, 11, 906-17	10.2	57
102	The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression. *Molecular Immunology*, **2015**, 68, 120-3	4.3	17
101	Antigen-presenting cells look within during influenza infection. *Nature Medicine*, **2015**, 21, 1123-5	50.5	4
100	Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination. *Journal of Immunology*, **2015**, 194, 2696-705	5.3	47
99	Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. *Mucosal Immunology*, **2015**, 8, 1060-71	9.2	95
98	Endogenous Murine BST-2/Tetherin Is Not a Major Restriction Factor of Influenza A Virus Infection. *PLoS ONE*, **2015**, 10, e0142925	3.7	8
97	Respiratory DC Use IFITM3 to Avoid Direct Viral Infection and Safeguard Virus-Specific CD8+ T Cell Priming. *PLoS ONE*, **2015**, 10, e0143539	3.7	23
96	Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. *Current Opinion in Pharmacology*, **2014**, 17, 64-70	5.1	21
95	Inflammation conditions mature dendritic cells to retain the capacity to present new antigens but with altered cytokine secretion function. *Journal of Immunology*, **2014**, 193, 3851-9	5.3	23
94	Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system. *Journal of Biological Chemistry*, **2014**, 289, 9730-40	5.4	18

93	Hydrocortisone prevents immunosuppression by interleukin-10+ natural killer cells after trauma-hemorrhage. *Critical Care Medicine*, **2014**, 42, e752-61	1.4	33
92	A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. *Journal of Experimental Medicine*, **2014**, 211, 1585-600	16.6	172
91	Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. *Journal of Immunology*, **2013**, 191, 3534-44	5.3	11
90	Control of MHC II antigen presentation by ubiquitination. *Current Opinion in Immunology*, **2013**, 25, 109-148	7	21
89	Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. *Nature Immunology*, **2013**, 14, 238-45	19.1	153
88	Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. *Vaccine*, **2013**, 31, 2310-6	4.1	17
87	Consequences of direct and indirect activation of dendritic cells on antigen presentation: functional implications and clinical considerations. *Molecular Immunology*, **2013**, 55, 175-8	4.3	12
86	Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. *European Journal of Immunology*, **2013**, 43, 595-605	6.1	25
85	Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice. *Molecular Immunology*, **2012**, 50, 9-17	4.3	32
84	Shutdown of immunological priming and presentation after in vivo administration of adenovirus. *Gene Therapy*, **2012**, 19, 1095-100	4	3
83	DEC-205 is a cell surface receptor for CpG oligonucleotides. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16270-5	11.5	117
82	The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. *European Journal of Immunology*, **2012**, 42, 2889-900	6.1	43
81	Autophagy and mechanisms of effective immunity. *Frontiers in Immunology*, **2012**, 3, 60	8.4	18
80	Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. *Blood*, **2012**, 119, 5918-30	2.2	30
79	The molecular signature of tissue resident memory CD8 T cells isolated from the brain. *Journal of Immunology*, **2012**, 189, 3462-71	5.3	251
78	Serpinb9 (Spi6)-deficient mice are impaired in dendritic cell-mediated antigen cross-presentation. *Immunology and Cell Biology*, **2012**, 90, 841-51	5	13
77	Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation. *Journal of Leukocyte Biology*, **2012**, 92, 145-58	6.5	15
76	CD69 does not affect the extent of T cell priming. *PLoS ONE*, **2012**, 7, e48593	3.7	16

75	A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells. *Traffic*, **2011**, 12, 1677-85	5.7	58
74	GM-CSF increases cross-presentation and CD103 expression by mouse CD8+ spleen dendritic cells. *European Journal of Immunology*, **2011**, 41, 2585-95	6.1	80
73	The acquisition of antigen cross-presentation function by newly formed dendritic cells. *Journal of Immunology*, **2011**, 186, 5184-92	5.3	91
72	A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. *Journal of Immunology*, **2011**, 187, 1166-75	5.3	21
71	IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. *Journal of Immunology*, **2011**, 186, 3666-73	5.3	37
70	Differentiation of inflammatory dendritic cells is mediated by NF-B1-dependent GM-CSF production in CD4 T cells. *Journal of Immunology*, **2011**, 186, 5468-77	5.3	66
69	Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. *Immunology and Cell Biology*, **2011**, 89, 595-603	5	9
68	Factors determining the spontaneous activation of splenic dendritic cells in culture. *Innate Immunity*, **2011**, 17, 338-52	2.7	38
67	Reply to Burgdorf et al.: The mannose receptor is not involved in antigen cross-presentation by steady-state dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, E50-E51	11.5	4
66	Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways. *Journal of Immunology*, **2010**, 185, 2125-33	5.3	35
65	Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. *Molecular Immunology*, **2010**, 47, 1765-73	4.3	35
64	Found in translation: the human equivalent of mouse CD8+ dendritic cells. *Journal of Experimental Medicine*, **2010**, 207, 1131-4	16.6	104
63	Blood-stage Plasmodium berghei infection leads to short-lived parasite-associated antigen presentation by dendritic cells. *European Journal of Immunology*, **2010**, 40, 1674-81	6.1	37
62	Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses. *Journal of Immunology*, **2009**, 182, 4200-7	5.3	78
61	Cutting edge: B220+CCR9- dendritic cells are not plasmacytoid dendritic cells but are precursors of conventional dendritic cells. *Journal of Immunology*, **2009**, 183, 1514-7	5.3	36
60	Different cross-presentation pathways in steady-state and inflammatory dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20377-81	11.5	130
59	Endolysosomal proteases and their inhibitors in immunity. *Nature Reviews Immunology*, **2009**, 9, 871-82	36.5	99
58	Antigen presentation by dendritic cells in vivo. *Current Opinion in Immunology*, **2009**, 21, 105-10	7.8	127

57	The cell biology of cross-presentation and the role of dendritic cell subsets. *Immunology and Cell Biology*, **2008**, 86, 353-62	5	122
56	Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. *Nature Immunology*, **2008**, 9, 1244-52	19.1	183
55	Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. *Immunology and Cell Biology*, **2008**, 86, 200-5	5	80
54	Antigen-presentation properties of plasmacytoid dendritic cells. *Immunity*, **2008**, 29, 352-61	32.3	368
53	Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3029-34	11.5	128
52	Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 14509-14	11.5	152
51	Antigen-presenting cells and antigen presentation **2008**, 103-111		
50	Targeting the gut vascular endothelium induces gut effector CD8 T cell responses via cross-presentation by dendritic cells. *Journal of Immunology*, **2007**, 179, 5678-85	5.3	11
49	Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 17753-8	11.5	62
48	Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. *Journal of Experimental Medicine*, **2007**, 204, 2579-90	16.6	100
47	Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells. *Journal of Immunology*, **2007**, 178, 2094-103	5.3	34
46	Hold on, the monocytes are coming!. *Immunity*, **2007**, 26, 390-2	32.3	17
45	Outside looking in: the inner workings of the cross-presentation pathway within dendritic cells. *Trends in Immunology*, **2007**, 28, 45-7	14.4	35
44	Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. *Nature Reviews Immunology*, **2007**, 7, 543-55	36.5	483
43	The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 10729-34	11.5	314
42	Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells. *Journal of Biological Chemistry*, **2006**, 281, 30485-91	5.4	41
41	Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. *Immunity*, **2006**, 25, 153-62	32.3	551
40	Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. *Nature Immunology*, **2006**, 7, 165-72	19.1	291

39	Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. *Seminars in Immunology*, **2005**, 17, 262-72	10.7	128
38	Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. *Blood*, **2005**, 105, 2465-72	2.2	162
37	Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. *Immunological Reviews*, **2005**, 207, 191-205	11.3	124
36	Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand. *European Journal of Immunology*, **2005**, 35, 3209-20	6.1	9
35	Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing. *European Journal of Immunology*, **2005**, 35, 3442-51	6.1	54
34	Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. *Advances in Immunology*, **2005**, 86, 241-305	5.6	123
33	Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. *Journal of Immunology*, **2005**, 174, 6592-7	5.3	409
32	Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. *Immunology and Cell Biology* , **2004**, 82, 91-8	5	70
31	Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. *Immunological Reviews*, **2004**, 199, 9-26	11.3	578
30	Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. *Nature Immunology*, **2004**, 5, 1143-8	19.1	339
29	Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. *Blood*, **2004** , 103, 2187-95	2.2	150
28	Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. *Journal of Immunology*, **2003**, 170, 4437-40	5.3	161
27	Most lymphoid organ dendritic cell types are phenotypically and functionally immature. *Blood*, **2003**, 102, 2187-94	2.2	292
26	Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect on presenilin exon 9 gamma- and epsilon-cleavage. *FEBS Journal*, **2003**, 270, 495-506		4
25	The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation. *Journal of Immunology*, **2003**, 171, 5003-11	5.3	70
24	Invariant chain controls the activity of extracellular cathepsin L. *Journal of Experimental Medicine*, **2002**, 196, 1263-9	16.6	72
23	Presentation of antigens by MHC class II molecules: getting the most out of them. *Molecular Immunology*, **2001**, 38, 329-46	4.3	83
22	MHC class II expression is regulated in dendritic cells independently of invariant chain degradation. *Immunity*, **2001**, 14, 739-49	32.3	125

21	Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. *Immunity*, **2001**, 15, 909-19	32.3	70
20	Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. *EMBO Journal*, **2000**, 19, 882-91	13	38
19	Proteolysis in MHC class II antigen presentation: who's in charge?. *Immunity*, **2000**, 12, 233-9	32.3	166
18	Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. *Journal of Cell Biology*, **1999**, 147, 775-90	7.3	200
17	Proteases involved in MHC class II antigen presentation. *Immunological Reviews*, **1999**, 172, 109-20	11.3	207
16	Cathepsin S required for normal MHC class II peptide loading and germinal center development. *Immunity*, **1999**, 10, 197-206	32.3	433
15	Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. *Science*, **1998**, 280, 450-3	33.3	577
14	Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 4516-21	11.5	231
13	Cathepsin S activity regulates antigen presentation and immunity. *Journal of Clinical Investigation*, **1998**, 101, 2351-63	15.9	226
12	Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. *Journal of Experimental Medicine*, **1997**, 186, 549-60	16.6	176
11	HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. *Tissue Antigens*, **1997**, 49, 580-7		33
10	Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. *Immunity*, **1996**, 4, 357-66	32.3	467
9	T-cell receptor usage in alloreactivity against HLA-B*2703 reveals significant conservation of the antigenic structure of B*2705. *Tissue Antigens*, **1996**, 47, 478-84		6
8	Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. *Tissue Antigens*, **1996**, 48, 509-18		37
7	Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. *European Journal of Immunology*, **1995**, 25, 2370-7	6.1	33
6	Structure of HLA-B27-specific T cell epitopes. Antigen presentation in B*2703 is limited mostly to a subset of the antigenic determinants on B*2705. *European Journal of Immunology*, **1994**, 24, 2548-55	6.1	15
5	Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. *Journal of Immunology*, **1994**, 152, 2317-23	5.3	37
4	Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B. *Journal of Experimental Medicine*, **1993**, 177, 613-20	16.6	36

3	Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2. *Journal of Immunology*, **1993**, 150, 2675-86	5.3	13
2	Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition. *Journal of Immunology*, **1992**, 149, 505-10	5.3	22
1	Dendritic Cell Subtypes199-217		